The evolving clinical testing landscape of genomic aberrations in solid tumors and hematological malignancies - Insights from evidence-based reviews for B-ALL and breast, brain, and renal cell neoplasia.

[1]  J. Houldsworth,et al.  Assessing Genomic Copy Number Alterations as Best Practice for Renal Cell Neoplasia: An Evidence-Based Review from the Cancer Genomics Consortium Workgroup. , 2020, Cancer genetics.

[2]  M. Shago,et al.  Evidence-based review of genomic aberrations in B-lymphoblastic leukemia/lymphoma: Report from the cancer genomics consortium working group for lymphoblastic leukemia. , 2020, Cancer genetics.

[3]  Marilyn M. Li,et al.  Copy number assessment in the genomic analysis of CNS neoplasia: An evidence-based review from the cancer genomics consortium (CGC) working group on primary CNS tumors. , 2020, Cancer genetics.

[4]  S. Kantarci,et al.  Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: An evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia. , 2018, Cancer genetics.

[5]  Trevor J Pugh,et al.  Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders. , 2018, Cancer genetics.

[6]  M. Slovak,et al.  Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group. , 2018, Cancer genetics.

[7]  M. Slovak,et al.  Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative n , 2018, Cancer genetics.